Biopharma Daily Stock Updates - 03/15/21

$XBI $148.22 +1% 📈

Covid Updates

$IBRX +1% Presents interim safety data from ph 1 study of AAV hAd5 T-cell covid vaccine. The independant review committee recommended the study continue with no trial modification. source

$MRNA +5% First patient dosed in ph 1 study of mRNA-1283 in next-gen covid vaccine. source

Pipeline Updates

$BLUE +3% Presents updated long term data for eli-cel in CALD at EMBT 2021. source

$AUPH +4% Positive cost-effectiveness assessment by ICER on LUPKYNIS for lupus nephritis (LN). source

$GILD +5% & $MRK +2% Co-develop and commercialize combo treatment of lenacapavir and islatravir for HIV. source

$ACRS -5% Completes enrollment in ph 2a study of ATI-1777 for atopic dermatitis. Data expected mid-2021. source

$CORT +1% Enrolled first patient in ph 1b trial of relacorilant + pembro (Keytruda) in adrenal cancer with cortisol excess. source

$GLTO -6% Interim update from DSMB of ph 2b GALACTIC-1 study. 3mg arm to continue, other treatment arms discontinued. source

$RUBY +80% Announces initial data from ph 1/2 trial of RTX-240 in advanced solid tumors. source

$EQ +5% Announces data from EQUATE study in acute graft-versus-host disease at EBMT 2021. source

$MGTA -1% Presents final ph 1 results of MGTA-145 in stem cell mobilization program at EBMT 2021. source

$URGN -1% Sponsored research agreement with Johns Hopkins to study RTGel in Glioblastoma (GBM). Nonclinical research expected to begin 2Q 2021. source

$SRRK +2% Will present TOPAZ interim data in spinal muscular atrophy at MDA 2021 on 3/18. source

$SLDB -17% Reported interim data from ongoing IGNITE ph 1/2 trial of SGT-001 in Duchenne muscular dystrophy. source

Financial Updates

$AVEO -2% Regains rights to AV-203 ex-US. source

$BHVN +0% Offering. source

$RUBY +80% Offering. source


*Disclaimer: Information provided on and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Big Movers™ is a trademark of Amp Biotech Research, LLC

©2021 by Biopharm IQ. Website by Awaken Studio.